Access the
Full Report
Request the Full Report →
This preview includes only a sample of the competitive insights available in the full version, which features 80+ pages of analysis, use cases, strategic frameworks, and data modeling — organized across five access tiers.
Report Summary
AI is no longer experimental — it's a competitive and regulatory necessity.
This CI report delivers strategic insight into how global life sciences firms are navigating AI safety compliance across pharmacovigilance, complaint handling, and regulatory reporting. It includes real-world case assessments, regional compliance gap analysis, and actionable strategic frameworks for pharma, biotech, and medtech decision-makers.
Key Findings
- Pfizer is automating adverse event intake: its AI platform handles case intake decisions, first at its Drug Safety Unit in Rome, with an end-to-end tool planned. Even large incumbents see real value but adopt cautiously, held back by speed, integration, and internal alignment.
- Market growth: the report estimates AI in safety compliance reaching $13.1B by 2034, an 18.8% CAGR, with pharmacovigilance the largest focus at 40% of deployment.
- Real-world risk — compliance gaps by region: only about 1 in 10 firms report full confidence in their regulatory AI-readiness, highlighting a significant and widening compliance gap across geographies.
- Regulation is moving: FDA issued draft guidance on AI for regulatory decision-making in January 2025, CIOMS published its AI in pharmacovigilance report on 4 December 2025, and a May 2026 provisional EU agreement moves high-risk AI dates to December 2027 and August 2028 (pending formal adoption).
Exhibits
Strategic Recommendations
- Align AI strategy with actual safety compliance needs, not just innovation targets.
- Invest in tools that support traceability, documentation, and cross-platform interoperability.
- Train regulatory and quality teams to interpret AI outputs under GxP.
Choose the intelligence level that fits your organization — from foundational overviews to full premium datasets with custom modeling and briefings.
Stay ahead of the next report
Not ready yet? Follow THE SIGNAL on LinkedIn for new intelligence briefs.
Sources for regulatory and company facts: Pfizer · CIOMS Working Group XIV · Gibson Dunn on the EU AI Act omnibus · Sidley Austin. Market and survey figures are LucidBio Intelligence estimates.